Valneva SE focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs.Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia. It sells its products in the United States, Canada, Germany, Austria, Nordics, other European countries, and internationally.
